Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
about
Cancer immunotherapy: moving beyond current vaccinesSynopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and ImmunotherapyLung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionTherapeutic cancer vaccines: past, present, and futureLung cancer vaccinesCancer vaccinesLung cancer vaccines: current status and future prospectsIs the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Ovarian cancer immunotherapy: opportunities, progresses and challengesLung cancer immunotherapy.Role of GM-CSF signaling in cell-based tumor immunization.MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible?Immunotherapy for lung cancers.A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.Current status of autologous breast tumor cell-based vaccines.Biosafety studies of carrier cells infected with a replication-competent adenovirus introduced by IAI.3B promoterEvaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.Current status of immunotherapy for the treatment of lung cancer.Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer VaccinesNovel targeted agents in the treatment of lung cancer.Human cancer gene therapy with cytokine gene-modified cells.Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.The colony-stimulating factors and cancer.Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.Vaccines in cancer: GVAX, a GM-CSF gene vaccine.Clinical trials targeting lung cancer with active immunotherapy: the scope of vaccines.Immunotherapy for gynaecological malignancies.Immunotherapy of cancer in 2012.Adenovirus as vehicle for anticancer genetic immunotherapy.Individualised cancer therapeutics: dream or reality? Therapeutics construction.Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic realityBaylor's contribution to thoracic surgery and cardiac stem cell therapy for heart failure.Cancer vaccines: a clinical perspective.Present and future of lung cancer vaccines.A review of vaccine clinical trials for non-small cell lung cancer.Multiple vaccinations: friend or foe.Talabostat.Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies.Immunotherapy for metastatic prostate cancer
P2860
Q24548229-3DFB0560-6872-4373-8470-5C6350BDDFB1Q24798754-BB148075-A08B-4B44-90E1-8746D332E34AQ26850218-17A02189-712F-419E-BFA4-85AC108B77FCQ26863283-09C403EE-1457-42DA-8B6E-0743BD41A7A2Q27014375-2118DC11-6B6D-4A44-B05B-9DBDEC5A40A7Q27024438-3B20F153-4B44-4995-BF0D-C5648189AE0EQ28080849-3EE7348E-0BCF-412F-8259-6B06048EC920Q30370848-9273E01C-3A4F-47D5-A566-07EF039DDB91Q33702218-91D9A95F-C009-47E8-8A5B-D14C1B6B47A9Q34146503-4D2EF6CC-61FD-4FCF-89B9-ED2E9E9499F1Q34147010-7E63CFB2-BE45-461A-985F-DA3C98A4250DQ34161849-E97B7A53-0BE8-4210-9E9F-96A57C03D659Q34364763-B705044A-ECCA-4548-A5CE-2066BAE52690Q34557611-1FAAE30D-EAEE-416E-BB6B-58DEE54EDD7BQ34733314-6114AE11-2C34-43D5-B623-F3B12549C2C2Q35154214-D37F7CD4-7719-4D77-ABFF-E49914ECDF72Q35184239-5EE6F9BF-33B3-4CF8-B1FE-5A9CF5A98A47Q35466199-2EEC3EC2-33D4-415F-876D-C02735FD188BQ35667739-AEDE5726-DE55-49BA-997A-05BBCA23875EQ35774908-BA80C41A-31E3-41A2-9F8E-958A61BD863CQ35790783-2282CA8D-1D17-4027-9181-7329953BA611Q35907018-0DE0C74E-16FD-44CF-A3F4-B55B94DF6344Q35928330-D6055A2F-5EA1-4BDC-B7CD-D0B3A9672B00Q35936937-560F52BF-86F0-4B5D-9255-A1F9A9283ADDQ36062926-E9A3C834-D9FB-46AA-9E13-52BDAF5C0BA5Q36198632-3ECC429F-B20F-4D4A-9D54-9F1675AFBE46Q36235551-71F325D7-9682-4795-AC2A-85BF20A9E610Q36239661-DF73812F-664E-4EBF-88A3-14C1C8D9DDA5Q36243536-316BC00C-EF20-48C9-8293-E704802F5281Q36288930-F106C686-8922-408C-AC23-95164B208FAEQ36299931-55C6A58B-8266-4331-97BB-E194DDDE889EQ36326572-D3A0DE74-73C6-4B6C-886E-9878D0E5698DQ36360309-7B00CC76-CC13-4EDE-B986-B5BCFA7964DBQ36554683-D82D9668-E35B-43CA-BB8A-CF7AE60A7AB8Q36580586-0701E742-33AF-44E3-9882-42C485FBB472Q36675454-8D535FE8-4C30-40A1-BC83-D96020E4BA6DQ36734688-3FEFE5E3-8591-48F7-AA4F-A6F7D375EB9FQ36916883-606DF1F8-703A-48EB-A71C-E9A145A46325Q36946100-F4E7C666-11B1-44CE-8281-D6FDF8F10B34Q36949548-2A8FB68C-58E9-415C-B973-2602355886B1
P2860
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Granulocyte-macrophage colony- ...... in non-small-cell lung cancer.
@en
Granulocyte-macrophage colony- ...... in non-small-cell lung cancer.
@nl
type
label
Granulocyte-macrophage colony- ...... in non-small-cell lung cancer.
@en
Granulocyte-macrophage colony- ...... in non-small-cell lung cancer.
@nl
prefLabel
Granulocyte-macrophage colony- ...... in non-small-cell lung cancer.
@en
Granulocyte-macrophage colony- ...... in non-small-cell lung cancer.
@nl
P2093
P2860
P356
P1476
Granulocyte-macrophage colony- ...... in non-small-cell lung cancer.
@en
P2093
Bernard Fox
David Jablons
Flavia Borellini
John Nemunaitis
John W Smith
Kristen Hege
Phil Maples
Sayeh Morali
Scott Hamilton
P2860
P304
P356
10.1093/JNCI/DJH028
P407
P577
2004-02-01T00:00:00Z